Objective To evaluate whether N-acetylcysteine (NAC) infusion during the first week of life reduces the risk of death or bronchopulmonary dysplasia (BPD) in infants with extremely low birth weight.
may impair antioxidant defenses. The synthesis of glutathione does not appear to be limited by the activity of c-glutamylcysteine synthetase even in preterm infants, 7 but rather by the availability of cysteine. In this respect, preterm infants are at a disadvantage, because the transsulfuration pathway from methionine into cysteine is not functional as a result of deficient activity of cystathionase. 8 During parenteral nutrition of immature infants, cysteine is the first amino acid to show decreased plasma levels. 9 Several trials of antioxidant treatment of preterm neonates to prevent BPD have been performed, with varying success. Neither vitamin A 10 nor vitamin E 11 has a consistent effect in the risk of BPD or death in infants with extremely low birth weight. Intratracheal administration of copper-zincsuperoxide dismutase did not reduce the incidence of BPD, but there was less pulmonary morbidity at age 1 year. 12 Given the important role of glutathione in antioxidant defense and the relative lack of glutathione in preterm infants, a rational approach to treatment would be to replenish glutathione stores. However, glutathione itself crosses cell membranes poorly, and its rate-limiting precursor, cysteine, is unstable in solutions. 13 N-acetylcysteine (NAC) is a precursor of cysteine and is by itself a free radical scavenger. 14 Furthermore, it is available as a registered drug for intravenous use to treat acetaminophen poisoning. NAC enters the cell and is deacetylated to cysteine, 15 which can replenish intracellular glutathione. NAC treatment reduced lung injury in adults with adult respiratory distress syndrome in some studies, 16, 17 but not in others. 18 We hypothesized that NAC would decrease morbidity and mortality in preterm infants because of its direct antioxidant effects and its ability to increase intracellular glutathione concentrations. The aim of this study was to evaluate whether NAC infusion during the first week of life reduces the risk of death or BPD in infants with extremely low birth weight.
METHODS
This randomized, double-blind, placebo-controlled, multicenter trial was performed in 10 academic neonatal intensive care units in Denmark, Finland, Iceland, Norway, and Sweden between March 1997 and April 2001. The research ethics committees of each institution and the National Agencies for Medicines in each country approved the protocol. Informed parental consent was obtained for each infant. Randomization was stratified for each center in blocks of 10 patients.
Infants with birth weights of 500 to 999 g who were on ventilator or nasal continuous positive airway pressure were eligible for enrollment before the age of 36 hours. Children with major congenital anomalies were excluded.
The infants were randomized either to intravenous NAC or to placebo group. For the first 67 patients, the preparations were Parvolex (N-acetyl-L-cysteine; 200 mg/ mL, Evans, UK), or 0.9% sodium chloride. The remainder received Mucomyst (N-acetyl-L-cysteine; 200 mg/mL) or its solvent without NAC, manufactured in identical vials by Draco Läkemedel AB, Lund, Sweden. Sets of 10 vials for each patient were numbered by the Pharmacy of Helsinki University Central Hospital for each center according to the randomization list and were used in consecutive order. The NAC vials were diluted 1:100 to a final concentration of 2 mg/ mL with 5% to 30% glucose solution, depending on the glucose requirement of the infant. The dilution procedure for the placebo infusion was identical. The infusion was started before the age of 36 hours and lasted for 6 days at a constant rate of 16 to 32 mg/kg/d, which was calculated on the basis of birth weight, with the smallest infants receiving the lowest dosages. This dosage was based on the results of our pharmacokinetic study of intravenous NAC in preterm babies 19 and aimed at a steady-state plasma concentration of 100 to 300 lmol/L. The target concentration was based both on a clinical study in adults with myocardial infarction 20 and on our unpublished work on cultured cells exposed to oxidants. The patients were treated according to the routine procedures in each intensive care unit and received parenteral and usually some enteral nutrition. Intravenous amino acids (Vaminolac, Fresenius-Kabi, Uppsala, Sweden, containing 1 mg/mL cysteine + cystine) were started on day 1 or 2, with the first dose 8 mL/kg/d, increasing daily to as much as 40 to 60 mL/ kg/d. Ultrasound examinations of the brain were performed at least once during the first week and at the age of 28 days. To describe the radiological severity of BPD, chest radiographs were taken at the ages of 28 days and 36 gestational weeks and classified according to Weinstein et al 21 and Toce et al 22 by one radiologist. To ensure compliance and to evaluate drug metabolism plasma NAC, cysteine, and glutathione concentrations were assayed by using a high-performance liquid chromatography method with penicillamine as the internal standard. 23 In short, disulfides were first reduced by dithiothreitol to free sulfhydryls, which were then derivatized with monobromobimane. Hence, the values we report here are for total NAC and total cysteine, which include various NAC and cysteine-containing disulfides in addition to free monomeric NAC and cysteine. A reversed-phase C-18 column was used to separate the adducts, and quantitation was performed by using a fluorescence detector.
To detect possible side effects caused by NAC, laboratory tests, including hemoglobin, white blood cell count, thrombocytes, alanine aminotransferase, international standardized ratio of thromboplastin time, and serum urea level were followed during the first 2 weeks. Blood pressure, heart rate, and oxygen saturation were monitored continuously during the study period, with special attention to the mean arterial blood pressure during 1 hour before and the first 6 hours after the start of the infusion. Relevant complications were recorded daily according to the requirements of the drug company.
The primary outcome was death by 36 gestational weeks or BPD, defined as any supplementary oxygen requirement at 36 gestational weeks. The severity of BPD was classified according to a recent proposal. 1 Secondary outcome measures were requirement of supplemental oxygen at the age of 28 days, duration of ventilator or nasal continuous positive airway pressure treatment, weight gain, and the incidence of other reactive oxygen species-related diseases: intraventricular hemorrhage (IVH) classified according to the criteria of Papile et al, 24 periventricular leukomalacia (PVL) according to the criteria of Trounce et al, 25 necrotizing enterocolitis (NEC) grade III or higher (NEC needing surgical treatment) according to Bell et al, 26 and retinopathy of prematurity (ROP) classified as the stage of disease in the more severely affected eye, based on the International Classification of Retinopathy of Prematurity. 27 Our sample size calculation was based on the statistics during a 2-year period of 1993 to 1995 in the Hospital for Children and Adolescents, Helsinki University Central Hospital, which showed that 46% of babies weighing <1000 g at birth either died or developed BPD by the time they reached the age of 36 gestational weeks. To detect a 33% reduction in BPD or death with NAC treatment with a power of 80% and a level of significance of 5% with a two-tailed test, the sample size was estimated to be 180 in each group.
All data for eligible enrolled infants were analyzed on an intention-to-treat basis. Baseline data for the treatment groups were compared by using the t test for continuous variables or the Mann-Whitney U test, as appropriate. Categorical baseline characteristics and outcomes were analyzed by using the v 2 test. All statistical tests were twotailed. Logistic regression was used to analyze the outcomes. Data were analyzed by using the SPSS 10.0 statistical package (SPSS, Inc, Chicago, Ill).
RESULTS
A total of 397 infants were enrolled in the study, but six infants were excluded from the analyses, one because of parental refusal and five because of major congenital anomalies diagnosed after the enrollment (one transposition of great arteries, two tetralogy of Fallot, one major ventricular septal defect, and one anal atresia). After the exclusion of these infants, 391 infants participated in the study: 194 in the NAC group and 197 in the placebo group. In two cases, the infusion was discontinued because of dosage error, and the code was opened (one NAC, one placebo). These cases are included in the analyses. There were no statistically significant differences in the baseline characteristics between the treatment groups (Table I) .
There was no difference in the primary outcome of death or BPD at the age of 36 gestational weeks between the NAC and placebo groups (Table II) . In the NAC group, 51% of the infants had BPD or had died, compared with 49% of infants in the placebo group (odds ratio, 1.0; 95% confidence interval, .7-1.6). Mortality at the age of 36 gestational weeks between the groups did not differ significantly: 18% in the NAC group, 14% in the placebo group. The incidence of BPD in infants alive at 36 gestational weeks was also similar. The severity of BPD was similar in the NAC and placebo group (Figure) . When the infants were divided into two subgroups according to their birth weight (cutoff, 750 g; Table II ) or gestational age (cutoff, 27 weeks; data not shown), no significant differences were noted in the incidence of BPD or death between the NAC or placebo treatments. Figure.
The severity of BPD, classified as mild, moderate, or severe according to Jobe and Bancalari. 1 One patient in the placebo group was lost to follow-up, and definite classification could not be performed.
At the age of 28 days, there was no significant difference in mortality or need of supplemental oxygen. Also, the mean percentage of oxygen required at the age of 28 days was similar: 31.2% in the NAC group and 30.7% in the placebo group. There was no statistically significant difference in the need of respiratory support between the groups. The median duration of ventilator treatment was 5 and 6 days, the median duration of nasal continuous positive airway pressure treatment was 24 and 27 days, and the median duration of any mechanical respiratory support was 37 and 42 days in the NAC and placebo groups, respectively.
The incidences of the other outcome measures are presented in Table III . There were no significant differences in the incidence of IVH, NEC, patent ductus arteriosus, PVL, or ROP between the two groups, ascertained at death or at the age of 36 gestational weeks. Also, the weight gain from birth to the age of 36 gestational weeks was similar in both groups. The use of postnatal steroids did not differ between the NAC and placebo groups.
Chest radiographs were taken of 260 infants at the age of 28 days and in 230 infants at the age corresponding to 36 gestational weeks. No difference was found at either age: the scores according to Weinstein et al 21 at 36 weeks were 3.0 ± 1.3 and 2.9 ± 1.2 and the scores according to Toce et al 22 were 4.4 ± 2.0 and 4.1 ± 1.8 in the NAC and placebo groups, respectively.
In the patient group receiving NAC, the mean plasma concentration of NAC was 170 lmol/L (range, 0-548 lmol/ L) on day 3 and 172 lmol/L (range, 0-351 lmol/L) on day 7, just before the 6-day infusion was stopped. On day 3, the mean plasma cysteine concentration was 108 lmol/L (range, 46-243 lmol/L) in the NAC group and 125 lmol/L (range, 44-253 lmol/L) in the placebo group (P = .01). On day 7, the mean plasma cysteine level was 144 lmol/L (range, 37-358 lmol/L) and 169 lmol/L (range, 40-390 lmol/L) in the NAC and placebo groups, respectively (P = .02). Although there was a difference between the group means, the increase in the plasma cysteine concentration from day 3 to day 7 was similar. The mean plasma glutathione concentrations were 19 lmol/L (range, 2-68 lmol/L) and 21 lmol/L (range, 2-59 lmol/L) on day 3, and 19 lmol/L (range, 2-33 lmol/L) and 23 lmol/L (range, 2-51 lmol/L) on day 7 in the NAC and placebo groups, respectively.
No differences were found between the treatment groups in blood pressure or in laboratory tests during the first 2 weeks of life. No adverse effects were observed that could be ascribed to NAC.
DISCUSSION
Our trial showed that a 6-day course of intravenous NAC did not prevent death or bronchopulmonary dysplasia in infants with extremely low birth weight. The reasons for this outcome can be sought either in a faulty basic rationale for the study or in the design and implementation of the trial. An optimal strategy to prevent lung injury should be based on an understanding of its pathogenesis.
In the infant with extremely low birth weight, structural immaturity and surfactant deficiency necessitate mechanical ventilation and oxygen administration, both of which contribute to an inflammatory response. Oxidative stress in preterm infants is indicated by lower reduced and higher oxidized glutathione concentrations in plasma of preterm infants compared with term infants, 28 and lower reduced glutathione levels in tracheal aspirates of preterm infants developing BPD. 29 Glutathione peroxidase is important for removal of intracellular hydrogen peroxide and lipid peroxides, and glutathione is a direct scavenger of oxidants both intracellularly and extracellularly. Its role in lung protection is suggested by the high concentrations of glutathione in the lining fluid of lower airways and alveoli, with a transient postnatal decrease in preterm infants. 6 NAC may not be the most effective glutathione precursor, but it is available as a registered drug. Furthermore, NAC itself is a potent scavenger of the hydroxyl radical and hypochlorous acid, is somewhat slower to react with hydrogen peroxide, and is unreactive with superoxide. 30 In animal experiments, intraperitoneally administered NAC ameliorated hyperoxic lung injury in guinea pigs. 31 Lipopolysaccharide-induced lung damage in rats was also attenuated by NAC, apparently because of scavenging of free radicals and inhibition of neutrophil oxidant production. 32 Human studies of both the biochemical and clinical effects of NAC have been inconclusive or conflicting, but the trials have been small. In adult respiratory distress syndrome, NAC improved oxygenation and lung function but had no significant effect on mortality. 16, 17 Apart from acetaminophen poisoning and genetic disorders of glutathione metabolism, intravenous NAC has not been studied in children. A clinical trial to test the applicability of NAC for prevention of BPD thus seemed warranted.
The subjects of our trial, infants weighing <1000 g at birth, represent a high-risk group with respect to the primary outcome measures, and a reasonable one third reduction in the incidence of death or BPD was the basis for sample size calculation. The target number of patients was recruited, and thus, a significant effect of NAC on these outcomes was ruled out. However, because the incidence of other complications of immaturity is lower, potential beneficial effects of NAC on IVH, NEC, PVL, and ROP cannot be evaluated on the basis of this trial, even though the incidence of PVL was 39% higher in the control group than in the NAC group. A considerably larger trial would be required to demonstrate a beneficial effect of NAC on hypoxic-ischemic brain injury in newborn infants, which has been shown in experimental animals. 33 N-acetylcysteine infusion was timed over the 6-day period, during which several biochemical indicators of oxidant effects increase in plasma, 34 in tracheal aspirates, 35 and expired air. 36 The largest change in the oxygen environment of the infant occurs immediately after birth, and usually at that time, ventilatory assistance is also initiated. An earlier start of NAC treatment could therefore have been more effective, but on the other hand, the trial would have recruited several infants who were weaned from the ventilator by age 36 hours. Whether a longer intervention could have been effective remains unclear.
To scavenge free radicals effectively and provide substrate for glutathione synthesis, an adequate dose of NAC must be given. There are no guidelines for the use of NAC in immature infants, and the desired therapeutic effect must be weighed against the risk of side effects. The dosage regimen based on our pharmacokinetic study 19 succeeded in maintaining the target concentration of 200 lM in most of the infants. Whether a higher dose would have influenced the primary outcome measures is a matter of speculation. Side effects noted in patients treated for acetaminophen poisoning include hypotension, bronchospasm, and a decrease in blood coagulation factors, but no adverse effects attributable to NAC were observed in our trial. The scavenging function of NAC is exerted by the intact molecule, but it must be deacetylated to cysteine to act as a glutathione precursor. Adult human liver and endothelial cells are able to deacetylate NAC, 37 but there is no information on the development of N-acetylase activity in any human tissue. Because in our study the change in plasma total cysteine concentration during the NAC infusion did not differ from that in the placebo infants, intravenous NAC may be poorly deacetylated in preterm infants. In a study of intravenous amino acid solutions for preterm infants, more than half of the NAC dose was excreted unchanged, and it had no demonstrable effect on plasma cysteine levels. 38 Our unpublished studies have shown that NAC is able to reduce cysteine from cystine and from mixed disulfides. Thus, even if NAC itself were a poor substrate for glutathione synthesis, its potential benefits as an antioxidant would depend on its ability to scavenge oxidants chemically and to liberate cysteine from disulfides. Glutathione is mainly intracellular, and the goal for NAC treatment was to increase glutathione concentration in the cells. This could unfortunately not be studied. NAC infusion did not increase plasma glutathione or cysteine concentrations. The question remains open whether interventions increasing intracellular glutathione levels protect from the development of BPD.
In conclusion, no beneficial effects of NAC with the dosage used could be demonstrated at 36 weeks. An ongoing follow-up of the surviving infants will show whether the long-term pulmonary outcome can be improved with early NAC treatment, as was recently reported for infants treated at birth with recombinant human CuZn superoxide dismutase. 12 
